{
  "docId": "019de075-12bd-74a7-bc75-4587e4948a57",
  "docSlug": "9c54f748d4238e6a3a690a4101a45e99",
  "documentTitle": "Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "deck",
  "documentKindLabel": "Deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 50,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "key_messages",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 10,
  "notes": "The chart uses a vertical axis to categorize drugs by mechanism of action (α4β7, IL-23s, TNFαs, S1P1s, JAKs) and a horizontal axis for efficacy (Pbo-adjusted clinical remission %).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-12bd-74a7-bc75-4587e4948a57/15",
  "deckHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57",
  "deckJsonHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57.json",
  "deckAnchorHref": "/decks/019de075-12bd-74a7-bc75-4587e4948a57#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.45,
        "x": 0.52,
        "y": 0.18
      },
      "kind": "chart",
      "text": "UC Maintenance Efficacy Pbo-adjusted clinical remission %",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c8ee660-d4f3-4a27-ba5d-c58cb2b7ae25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.02,
        "y": 0.33
      },
      "kind": "list",
      "text": "Vedolizumab specifically binds α4β7 integrin, selectively blocking gut lymphocyte trafficking. Leading maintenance efficacy data in UC replicated in two P3 studies; efficacy on par with upadacitinib 15mg dose; superior head-to-head vs adalimumab (Humira) in UC. Clean safety profile since approval in 2014. #1 biologic in IBD bio-naïve patients in the US.1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a79aad1e-2cc6-43be-a342-5d0a7b18f4b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.02,
        "y": 0.215
      },
      "kind": "quote",
      "text": "“Entyvio (vedolizumab) is the safest drug and one of the most effective for UC.” – US KOL",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e2215acb-ed1c-4f81-a3b7-2b07488595e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.95,
        "x": 0.02,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "1. Takeda JPM 2023 presentation. Figure data sources: Vedolizumab IV and SC data from VISIBLE 1 P3 study. Ustekinumab, adalimumab, infliximab, golimumab, ozanimod, tofacitinib, upadacitinib data from labels. Mirikizumab data from phase 3 LUCENT-2 study. Upadacitinib data shown in lighter red is 15mg preferred dose, darker red higher 30mg dose. Maintenance studies shown included patients who achieved clinical response at induction.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a93a97e4-2960-4f8f-9f19-153d80246a42",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.04
      },
      "kind": "title",
      "text": "Vedolizumab maintenance efficacy and exquisite safety make it preferred biologic in moderate-to-severe UC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e64a54eb-c3ee-4850-8add-87aee620294d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "74bfb30f-fe37-4a95-a77b-03f1a8442fe6",
      "evidence": "The use of a bar chart to display 'UC Maintenance Efficacy Pbo-adjusted clinical remission %' shows consideration for effective chart selection.",
      "confidence": 0.6
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "db9e9849-cc2c-40cd-a15e-854c0af810ff",
      "evidence": "The slide presents information in bullet points, effectively using lists to communicate key messages.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "ed245e41-e31c-4886-899a-a882fb0102c4",
      "evidence": "Comparison of efficacy across multiple drug classes",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}